×
Components:
Lacidipine
Method of action:
Hypotensive
Available in countries
See all
close
Medically reviewed by Kovalenko Svetlana Olegovna, PharmD. Last updated on 2019.12.15

Qualitative and quantitative composition

Lacidipine

Pharmaceutical form

Film-coated tablet

Therapeutic indications

The information provided in Therapeutic indications of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Therapeutic indications in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Lacidipina Generis is indicated for the treatment of hypertension either alone or in combination with other antihypertensive agents, including ß-adrenoceptor antagonists, diuretics, and ACE-inhibitors.

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Posology

Adults

The treatment of hypertension should be adapted to the severity of the condition, and according to the individual response.

The recommended initial dose is 2 mg once daily. The dose may be increased to 4 mg (and then, if necessary, to 6 mg) after adequate time has been allowed for the full pharmacological effect to occur. In practice, this should not be less than 3 to 4 weeks. Daily doses above 6 mg have not been shown to be significantly more effective. Lacidipina Generis tablets should be taken at the same time each day, preferably in the morning. Treatment with Lacidipina Generis may be continued indefinitely.

Patients with hepatic impairment

Lacidipina Generis is metabolised primarily by the liver and therefore in patients with hepatic impairment, the bioavailability of Lacidipina Generis may be increased and the hypotensive effect enhanced. These patients should be carefully monitored, and in severe cases, a dose reduction may be necessary.

Patients with kidney disease

As Lacidipina Generis is not cleared by the kidneys, the dose does not require modification in patients with kidney disease.

Paediatric population

The safety and efficacy of Lacidipina Generis in children and adolescents aged below 18 have not been estabilished. No data are available.

Method of administration

For oral administration

Contraindications

The information provided in Contraindications of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Lacidipina Generis tablets are contraindicated in patients with known hypersensitivity to any ingredient of the preparation.

Lacidipina Generis should only be used with great care in patients with a previous allergic reaction to another dihydropyridine because there is a theoretical risk of cross-reactivity.

As with other calcium antagonists, Lacidipina Generis should be discontinued in patients who develop cardiogenic shock and unstable angina. In addition, dihydropyridines have been shown to reduce coronary arterial blood-flow in patients with aortic stenosis and in such patients Lacidipina Generis is contraindicated.

Lacidipina Generis should not be used during or within one month of a myocardial infarction.

<) the use of the product is contraindicated.

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

In specialised studies Lacidipina Generis has been shown not to affect the spontaneous function of the SA node or to cause prolonged conduction within the AV node. However, the theoretical potential for a calcium antagonist to affect the activity of the SA and AV nodes should be noted, and therefore Lacidipina Generis should be used with caution in patients with pre-existing abnormalities in the activity of the SA and AV nodes.

As has been reported with other dihydropyridine calcium channel antagonists, Lacidipina Generis should be used with caution in patients with congenital or documented acquired QT prolongation. Lacidipina Generis should also be used with caution in patients treated concomitantly with medications known to prolong the QT interval such as class I and III antiarrhythmics, tricyclic antidepressants, some antipsychotics, antibiotics (e.g. erythromycin) and some antihistamines (e.g. terfenadine).

As with other calcium antagonists, Lacidipina Generis should be used with caution in patients with poor cardiac reserve.

There is no evidence that Lacidipina Generis is useful for secondary prevention of myocardial infarction.

The efficacy and safety of Lacidipina Generis in the treatment of malignant hypertension has not been established.

Lacidipina Generis should be used with caution in patients with impaired liver function because antihypertensive effect may be increased.

There is no evidence that Lacidipina Generis impairs glucose tolerance or alters diabetic control.

Excipients

This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Lacidipina Generis tablets may cause dizziness. Patients should be warned not to drive or operate machinery if they experience dizziness or related symptoms.

Undesirable effects

The information provided in Undesirable effects of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Lacidipina Generis tablets are generally well tolerated.

Some individuals may experience minor side effects which are related to its known pharmacological action of peripheral vasodilation. Such effects, indicated by a hash #, are usually transient and usually disappear with continued administration of Lacidipina Generis at the same dosage.

Data from large clinical studies (internal and published) were used to determine the frequency adverse effects.

Adverse effects have been ranked under headings of frequency using the following convention:

very common:

common:

uncommon:

rare:

very rare:

not known:

>1/10

> 1/100, <1/10

> 1/1000, <1/100

> 1/10000, <1/1000

<1/10000

cannot be estimated from the available data

In each group adverse effects are presented with decreasing severity.

Pysichiatric disorders

Very rare:

depression

Nervous system disorders

Common:

#headache, #dizziness

Very rare:

tremor

Cardiac disorders

Common:

#palpitations, tachycardia

Uncommon:

syncope, hypotension

As with other dihydropyridines aggravation of underlying angina pectoris has been reported in a small number of individuals, especially at the start of treatment. This is more likely to happen in patients with symptomatic ischaemic heart disease. Lacidipina Generis should be discontinued under medical supervision in patients who develop unstable angina.

Vascular disorders

Common:

#flushing (especially of face)

Uncommon:

hypotension

Gastrointestinal disorders

Common:

abdominal discomfort, nausea

Uncommon:

gingival hyperplasia

Skin and subcutaneous tissue disorders

Common:

rash, erythema, pruritus

Rare:

angioedema, urticaria

Musculoskeletal and connective tissue disorders

Rare:

muscle cramps

Renal and urinary disorders

Common:

polyuria

General disorders and administration site conditions

Common:

asthenia, #oedema

Investigations

Common:

blood alkaline phosphatase increased

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme: www.mhra.gov.uk/yellowcard.

Overdose

The information provided in Overdose of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Symptoms

There have been no recorded cases of Lacidipina Generis tablets overdosage. The expected symptoms could comprise prolonged peripheral vasodilation associated with hypotension and tachycardia. Bradycardia or prolonged AV conduction could occur.

Therapy

There is no specific antidote. Standard general measures for monitoring cardiac function and appropriate supportive and therapeutic measures should be used.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Pharmacotherapeutic group: Calcium channel blockers, dihydropyridine derivatives

ATC code: C08CA09

Mechanism of action

Lacidipina Generis is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle.

Pharmacodynamic effects

Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure.

In a study of ten patients with a renal transplant, Lacidipina Generis has been shown to prevent an acute decrease in renal plasma flow and glomerular filtration rate about six hours after administering oral cyclosporin. During the trough phase of cyclosporin treatment, there was no difference in renal plasma flow and glomerular filtration rate between patients with or without Lacidipina Generis.

Following the oral administration of 4 mg Lacidipina Generis to volunteer subjects, a minimal prolongation of QTc interval has been observed (mean QTcF increase between 3.44 and 9.60 ms in young and elderly volunteers). This was not associated with any adverse clinical effects or cardiac arrhythmias on monitoring.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Absorption

Lacidipina Generis is a highly lipophilic compound; it is rapidly absorbed from the gastrointestinal tract following oral dosing.

Absolute bioavailability averages about 10% due to extensive first-pass metabolism in the liver.

Peak plasma concentrations are reached between 30 and 150 minutes.

Biotransformation

The principal four metabolites possess little, if any, pharmacodynamic activity.

The drug is eliminated primarily by hepatic metabolism (involving cytochrome P450 CYP3A4). There is no evidence that Lacidipina Generis causes either induction or inhibition of hepatic enzymes.

Elimination

Approximately 70% of the administered dose is eliminated as metabolites in the faeces and the remainder as metabolites in the urine.

The average terminal half-life of Lacidipina Generis ranges from between 13 and 19 hours at steady state.

Preclinical safety data

The information provided in Preclinical safety data of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

In acute toxicity studies, Lacidipina Generis has shown a wide safety margin.

In repeated dose toxicological studies, findings in animals, related to the safety profile of Lacidipina Generis in man, were reversible and reflected the pharmacodynamic effect of Lacydipine.

No data of clinical relevance have been gained from in vivo and in vitro studies on reproduction toxicity, genetic toxicity or oncogenicity.

Incompatibilities

The information provided in Incompatibilities of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable.

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of Lacidipina Generis is based on data of another medicine with exactly the same composition as the Lacidipina Generis of the medicine (Lacidipine). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Lacidipina Generis directly from the package or from the pharmacist at the pharmacy.
more... close

The tablets should not be removed from their foil pack until required for administration.

No special requirements for disposal.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Site feedback

How easy to use our site?

Commentary is required, without it we won't know how to become better
The maximum length of review is 1000 symbols

Thanks!

You help us to become better